- Poster to be presented in
a late-breaking abstract session at the Society for
Immunotherapy of Cancer (SITC) on Saturday,
November 9, 2024
ROCKVILLE, Md., Oct. 30,
2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the
"Company"), a U.S.-based, global biotech company exclusively
focused on the development of highly differentiated immunotherapies
for the treatment of cancer, today announced the presentation
of a poster highlighting Phase 1 optimized dose estimation data for
givastomig monotherapy (TJ033721/ABL111), a novel first-in-class
Claudin18.2 (CLDN18.2) and 4-1BB bispecific antibody, at SITC 2024.
The conference is being held in Houston,
Texas, from November 6-10,
2024.
Presentation Details:
- Title: Optimal dose estimation using an integrated approach
from Phase I data of givastomig, a novel Claudin18.2×4-1BB
bispecific antibody
- Poster #: 1474
- Presenter: J.A. Yanez, I-Mab
- Session: Poster Hall, George R. Brown Convention
Center
- Session Date: Saturday, November
9, 2024
- Session Time: 9:00 am CDT to 8:30
pm CDT, Level 1 – Exhibit Halls AB
A full copy of the poster will be available on the I-Mab website
under the "Innovation, Publications & Presentations" tab on
November 9, 2024.
About Givastomig
Givastomig (TJ033721 / ABL111) is a bispecific antibody
targeting Claudin (CLDN) 18.2-positive tumor cells. It
conditionally activates T cells through the 4-1BB pathway in the
tumor microenvironment where CLDN18.2 is expressed. Givastomig
appears to maintain strong tumor binding and anti-tumor activity,
attributable to a synergistic effect of proximal interaction with
CLDN18.2 and 4-1BB, while minimizing liver toxicity and systemic
immunotoxicity commonly seen with other emerging 4-1BB-based
product candidates. In March 2022,
the U.S. Food and Drug Administration (FDA) granted Orphan Drug
Designation for givastomig for the treatment of gastric cancer,
including cancer of the gastroesophageal junction. A Phase
1b study is ongoing evaluating
givastomig, in combination with standard-of-care nivolumab plus
chemotherapy, in treatment-naïve patients with gastric cancers,
including gastroesophageal cancer (NCT04900818).
The program is being jointly developed through a global
partnership with ABL Bio, in which I-Mab is the lead party and
shares worldwide rights, excluding China and South
Korea, equally with ABL Bio.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company
exclusively focused on the development of highly differentiated
immunotherapies for the treatment of cancer. I-Mab has established
operations in Rockville, Maryland,
and Short Hills, New Jersey. For more information, please
visit https://www.i-mabbiopharma.com and follow us
on LinkedIn and X.
I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-to-present-givastomig-phase-1-optimal-dose-estimation-data-at-sitc-2024-302290887.html
SOURCE I-Mab Biopharma
